135 related articles for article (PubMed ID: 38314144)
1. Etoposide-induced SENP8 confers a feed-back drug resistance on acute lymphoblastic leukemia cells.
Sun S; Cheng Y; Hou W; Yan Y; Meng T; Li H; Xiao N
Biochem Biophys Rep; 2024 Mar; 37():101650. PubMed ID: 38314144
[TBL] [Abstract][Full Text] [Related]
2. Central role for endothelial human deneddylase-1/SENP8 in fine-tuning the vascular inflammatory response.
Ehrentraut SF; Kominsky DJ; Glover LE; Campbell EL; Kelly CJ; Bowers BE; Bayless AJ; Colgan SP
J Immunol; 2013 Jan; 190(1):392-400. PubMed ID: 23209320
[TBL] [Abstract][Full Text] [Related]
3. Deneddylating enzyme SENP8 regulates neuronal development.
Song JM; Kang M; Lee S; Kim J; Park S; Park DH; Lee S; Suh YH
J Neurochem; 2023 May; 165(3):348-361. PubMed ID: 36847487
[TBL] [Abstract][Full Text] [Related]
4. Clinical and In Vitro Studies on Impact of High-Dose Etoposide Pharmacokinetics Prior Allogeneic Hematopoietic Stem Cell Transplantation for Childhood Acute Lymphoblastic Leukemia on the Risk of Post-Transplant Leukemia Relapse.
Sobiak J; Kazimierczak U; Kowalczyk DW; Chrzanowska M; Styczyński J; Wysocki M; Szpecht D; Wachowiak J
Arch Immunol Ther Exp (Warsz); 2015 Oct; 63(5):385-95. PubMed ID: 26040247
[TBL] [Abstract][Full Text] [Related]
5. SENP8 limits aberrant neddylation of NEDD8 pathway components to promote cullin-RING ubiquitin ligase function.
Coleman KE; Békés M; Chapman JR; Crist SB; Jones MJ; Ueberheide BM; Huang TT
Elife; 2017 May; 6():. PubMed ID: 28475037
[TBL] [Abstract][Full Text] [Related]
6. Deneddylation by SENP8 restricts hepatitis B virus propagation.
Chen DV; Suzuki T; Itoh Y; Maeda Y; Hirano J; Haga S; Zhang H; Ito D; Matsuura Y; Okamoto T
Microbiol Immunol; 2021 Mar; 65(3):125-135. PubMed ID: 33433029
[TBL] [Abstract][Full Text] [Related]
7. Role of differential drug uptake, efflux, and binding of etoposide in sensitive and resistant human tumor cell lines: implications for the mechanisms of drug resistance.
Politi PM; Sinha BK
Mol Pharmacol; 1989 Mar; 35(3):271-8. PubMed ID: 2564628
[TBL] [Abstract][Full Text] [Related]
8. Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene.
Lorico A; Rappa G; Srimatkandada S; Catapano CV; Fernandes DJ; Germino JF; Sartorelli AC
Cancer Res; 1995 Oct; 55(19):4352-60. PubMed ID: 7671247
[TBL] [Abstract][Full Text] [Related]
9. Identifying de-NEDDylation inhibitors: Virtual high-throughput screens targeting SENP8.
Chen JJ; Schmucker LN; Visco DP
Chem Biol Drug Des; 2019 Apr; 93(4):590-604. PubMed ID: 30560590
[TBL] [Abstract][Full Text] [Related]
10. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.
Andoh T; Nishizawa M; Hida T; Ariyoshi Y; Takahashi T; Ueda R
Oncol Res; 1996; 8(6):229-38. PubMed ID: 8895198
[TBL] [Abstract][Full Text] [Related]
11. Altered gene expression in human leukemia K562 cells selected for resistance to etoposide.
Ritke MK; Yalowich JC
Biochem Pharmacol; 1993 Dec; 46(11):2007-20. PubMed ID: 8267650
[TBL] [Abstract][Full Text] [Related]
12. The molecular determinants of NEDD8 specific recognition by human SENP8.
Shin YC; Tang SJ; Chen JH; Liao PH; Chang SC
PLoS One; 2011; 6(11):e27742. PubMed ID: 22110750
[TBL] [Abstract][Full Text] [Related]
13. Etoposide (VP-16) with prednisone and vincristine for the treatment of refractory acute lymphoblastic leukemia.
Abromowitch M; Bowman WP; Ochs J; Rivera G
J Clin Oncol; 1985 Jun; 3(6):789-92. PubMed ID: 3859585
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia.
Kornblau SM; Estey E; Madden T; Tran HT; Zhao S; Consoli U; Snell V; Sanchez-Williams G; Kantarjian H; Keating M; Newman RA; Andreeff M
J Clin Oncol; 1997 May; 15(5):1796-802. PubMed ID: 9164187
[TBL] [Abstract][Full Text] [Related]
15. In vivo etoposide-resistant C6 glioma cell line: significance of altered DNA topoisomerase II activity in multi-drug resistance.
Taki T; Ohnishi T; Arita N; Hiraga S; Hayakawa T
J Neurooncol; 1998 Jan; 36(1):41-53. PubMed ID: 9525824
[TBL] [Abstract][Full Text] [Related]
16. Combined modalities of resistance in etoposide-resistant human KB cell lines.
Ferguson PJ; Fisher MH; Stephenson J; Li DH; Zhou BS; Cheng YC
Cancer Res; 1988 Nov; 48(21):5956-64. PubMed ID: 2844393
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of high-dose etoposide administered in combination with fractionated total-body irradiation as conditioning for allogeneic hematopoietic stem cell transplantation in children with acute lymphoblastic leukemia.
Chrzanowska M; Sobiak J; Grund G; Wachowiak J
Pediatr Transplant; 2011 Feb; 15(1):96-102. PubMed ID: 21159109
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of etoposide and methotrexate sensitivity by indomethacin in vitro.
Maca RD
Anticancer Drug Des; 1991 Nov; 6(5):453-66. PubMed ID: 1722410
[TBL] [Abstract][Full Text] [Related]
19. Effects of hsa-miR-9-3p and hsa-miR-9-5p on Topoisomerase II
Carvajal-Moreno J; Hernandez VA; Wang X; Li J; Yalowich JC; Elton TS
J Pharmacol Exp Ther; 2023 Feb; 384(2):265-276. PubMed ID: 36410793
[TBL] [Abstract][Full Text] [Related]
20. Tumor cell resistance to topoisomerase II poisons: role for intracellular free calcium in the sensitization by inhibitors or calcium-calmodulin-dependent enzymes.
Grabowski DR; Dubyak GR; Rybicki L; Hidaka H; Ganapathi R
Biochem Pharmacol; 1998 Aug; 56(3):345-9. PubMed ID: 9744572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
